Corcept Therapeutics reports positive Phase 2 BELLA trial results for Lifyorli in platinum‑resistant ovarian cancer
Corcept Therapeutics announced that Part A of its Phase 2 BELLA trial of Lifyorli (relacorilant) combined with nab‑paclitaxel and bevacizumab met its primary endpoints in platinum‑resistant ovarian cancer. The study of 95 patients showed a median progression‑free survival of 7.2 months and an objective response rate of 59%. Sub‑analyses indicated even stronger efficacy in patients who had not previously received bevacizumab, with median PFS of 8.1 months and ORR of 66%. No new safety signals were reported.
Why it matters
The company said the data support a potential label expansion for Lifyorli, which could improve its market position. Investors responded with a pre‑market rally, the stock rising 3.7% according to one source and 2.49% according to another.
Key facts
- 1The BELLA trial enrolled 95 patients. investing.com
- 2Median progression‑free survival was 7.2 months. tradingview.com
- 3Objective response rate was 59%. tradingview.com
- 4In the bevacizumab‑naïve subgroup, median PFS was 8.1 months. investing.com
- 5In the bevacizumab‑naïve subgroup, ORR was 66%. investing.com
- 688% of patients were alive at six months. investing.com
Open questions
- Pre‑market price gain is reported as 3.7% in material 2 and 2.49% in material 3.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.